As­traZeneca's Imfinzi fails main OS end­point in PhI­II for head and neck can­cer — and adding treme­li­mum­ab didn’t help, ei­ther

When As­traZeneca re­port­ed dis­ap­point­ing re­sults from the Phase III EA­GLE tri­al, the com­pa­ny point­ed to the KESTREL study — which tests its PD-L1 drug Imfinzi both …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER